-- 周五下午晚些时候，医疗保健类股下跌，纽约证券交易所医疗保健指数下跌0.2%，道富医疗保健精选行业SPDR ETF (XLV)下跌0.4%。 iShares生物科技ETF (IBB)下跌0.6%。 公司新闻方面，Moderna (MRNA)重申了其2026年营收增长预期，并公布了好于预期的第一季度业绩，这主要得益于新冠疫苗销售额的增长。尽管如此，该股仍下跌1.4%。 摩根士丹利表示，安进 (AMGN) 第一季度每股收益超预期主要得益于行政成本和税收的降低。安进股价下跌4.9%。 美国银行证券表示，礼来 (LLY) 的新型口服减肥药Foundayo的国际推广开局强劲，早期需求迅速增长。礼来股价上涨3.1%。 诺和诺德（Novo Nordisk，股票代码：NVO）将其用于治疗2型糖尿病的口服索马鲁肽药物更名为Ozempic。该药物此前以Rybelsus的名称销售。诺和诺德股价上涨3.9%。
Related Articles
Research
Research Alert: CFRA Maintains Hold Recommendation On Vale S.a.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our unchanged 12-month target price of USD18 is driven by an EV/EBITDA of 5.0x applied to our 2027 EBITDA estimate, above VALE's three-year average forward EV/EBITDA of 3.9x but below peers' average of 6.5x. We decrease our 2026 earnings per ADS estimate by BRL0.49 to BRL10.28 and our 2027 forecast by BRL0.45 to BRL10.52. Vale demonstrated robust operational performance in Q1 2026, with production records across multiple assets supporting 3% iron ore volume growth and double-digit gains in copper and nickel. However, cost pressures from BRL appreciation and higher oil prices pushed C1 costs to $23.6/t (+12% Y/Y), leading management to guide toward the upper end of 2026 cost guidance. Vale Base Metals is delivering significant value, with EBITDA more than doubling Y/Y. With expanded net debt at $17.8B and trending toward the midpoint of the $10B-$20B target range, management expressed confidence in distributing significant dividends and continuing buybacks through 2026 under current commodity prices.
$VALE
Research
Research Alert: CFRA Maintains Sell Rating On Shares Of Teradyne, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our target by $15 to $252, 29x our 2027 EPS view, above TER's three-year average (~25x), as broadening AI upside offsets customer concentration risks. We raise our 2026 EPS by $1.08 to $6.98 and 2027's by $1.30 to $8.70. Q1 2026 was another great quarter, but Q2 guidance (sales +87% Y/Y) spooked the bulls by coming in only near expectations rather than significantly outperforming. We have long cautioned of a potential reversal of recent strength given major customers' order lumpiness, and with today's selloff, we think valuation is starting to come back down to earth as investors pencil in a more pronounced sequential decline in 2H 2026. TER has also officially won some merchant GPU business, but its early results ($50M of revenue expected in 2026) are a bit underwhelming and further share gains are not a guarantee, dampening some of TER's near-term upside. In the meantime, we still think the memory shortage adds risks to industry activity in 2H 2026 and 2027 that are not appropriately priced in.
$TER
Insider Trading
Bloom Energy Insider Sold Shares Worth $9,765,000, According to a Recent SEC Filing
Shawn Marie Soderberg, Chief Legal Officer and Corporate Secretary, on April 29, 2026, sold 35,000 shares in Bloom Energy (BE) for $9,765,000. Following the Form 4 filing with the SEC, Soderberg has control over a total of 482,463 Class A common shares of the company, with 140,732 shares held directly and 341,731 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1664703/000119312526201723/xslF345X05/ownership.xml
$BE